AltMed Florida’s Director of Research and Development Wins Coveted Cannabis Chemistry Award

Dr. Jackie Salm will be honored at the 2020 National Meeting of the American Chemical Society for her groundbreaking research on the unique chemistry of the cannabis plant

AltMed Florida’s Director of Research and Development Dr. Jackie Salm has been announced as a 2020 ElSohly Award winner.

The ElSohly Awards, presented by the Cannabis Chemistry Subdivision of the American Chemical Society (ACS) were created to honor researchers at the forefront of cannabis science. The awards are named after cannabis research pioneer Dr. Mahmoud ElSohly, who has been running the only DEA-sanctioned cannabis farm at the University of Mississippi since 1980.

Dr. Salm will give a talk about her research at the National Meeting of the ACS in Philadelphia next spring. Her presentation at the Award Symposium is titled “Unique Terpene Metabolites as Descriptors of Cannabis Phenotypes.”

“Our hope with this research is to truly understand the complex chemistry of the Cannabis plant,” Dr. Salm said. “As many researchers in medicine know, the smallest changes in chemistry can dramatically affect how a patient’s body will react. There are so many claims in the industry that have never been proven or even researched, so we’re hoping to shed light on what’s really happening biochemically to create better, more reliable relief.”

This is Dr. Salm’s second ACS award. In 2016, she was awarded as the most read author for all of the ACS, with AltMed Florida’s Chief Scientific Officer Dr. Chris Witowski as the second author, on their publication about a potential antibiotic called darwinolide.

“For this 2020 ElSohly award, our research topic is on metabolomics, so the full chemical profile of the cannabis plant,” Dr. Salm said. “We’ve used this technique to differentiate strains and even shown how different extraction methods change terpene profiles of products. Our hope is to show that the chemical complexity of the cannabis plant requires medicine to make a big change in personalization for patients.”

The National ACS conference runs from March 22-26 in Philadelphia, and the ElSohly awards are presented at that time.


About Plants of Ruskin, LLC – d.b.a. AltMed Florida, LLC – With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.

About AltMed Enterprises – Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

About the ElSohly Awards – CANN or better known as Cannabis Chemistry Subdivision was founded in 2015 to build a home within the American Chemical Society for cannabis chemists established the first ever cannabis chemistry award known as the ElSohly Award Sponsored by Heidolph North America. The ElSohly Award provides researches, students, and industry professionals with resources to present their work at the ElSohly Award Symposium at the Spring National Meeting of the ACS.

Forward-Looking Statements – To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Dr. Jackie Salm, PhD

There are so many claims in the industry that have never been proven or even researched, so we’re hoping to shed light on what’s really happening biochemically to create better, more reliable relief.